LIVIVO - Search results -

Search results

Result 1 - 10 of total 49

Search options

Article: The effect of expandable versus static lordotic interbody implants in minimally invasive spine surgery: patient reported outcomes, sagittal alignment, and restoration of disc height and foraminal height.

Kucharzyk, Donald W / Budimir, Dushan / Waldorff, Erik I / Shum, Laura C / Vannabouathong, Christopher

2023 Volume 9, Issue 1, Page(s) 39–53

Abstract: Background: Pain and disability due to age-related spinal disorders are increasing due to a more active population placing greater demands on their musculoskeletal system. For patients requiring surgery, spinal fusion is typically indicated. Interbody ... ...

Abstract	Background: Pain and disability due to age-related spinal disorders are increasing due to a more active population placing greater demands on their musculoskeletal system. For patients requiring surgery, spinal fusion is typically indicated. Interbody fusion cages improve fusion rates and restore lordosis, disc height, and foraminal height. Static cages are offered in multiple conformations to account for anatomic variability; however, they have issues related to implant subsidence and loss of lordosis. Expandable cages were developed to address these drawbacks. Methods: Patients treated with either static or expandable transforaminal lumbar interbody fusion devices (ProLift Results: One hundred patients were included (Static: 50; Expandable: 50). Demographics between groups were similar, with some differences in comorbidities and spinal disease diagnosis. Radiographically, changes in disc height, foraminal height, and lordosis were significantly improved in the Expandable group up to 2 years (P<0.001). Improvements in patient reported outcomes were more favorable in the Expandable group. Conclusions: In patients who underwent transforaminal lumbar spinal fusion via minimally invasive surgery, the Expandable device group demonstrated significantly improved radiographic and patient reported outcomes compared to a static cage over 2 years.
Language	English
Publishing date	2023-01-09
Publishing country	China
Document type	Journal Article
ZDB-ID	2874556-5
ISSN	2414-4630 ; 2414-469X
ISSN (online)	2414-4630
ISSN	2414-469X
DOI	10.21037/jss-22-55
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Combination radiofrequency ablation and vertebral cement augmentation for spinal metastatic tumors: A systematic review and meta-analysis of safety and treatment outcomes.

Chen, Andrew L / Sagoo, Navraj S / Vannabouathong, Christopher / Reddy, Yashas / Deme, Sathvik / Patibandla, Sahiti / Passias, Peter G / Vira, Shaleen

North American Spine Society journal

2024 Volume 17, Page(s) 100317

Abstract: Background: The treatment of spine metastases continues to pose a significant clinical challenge, requiring the integration of multiple therapeutic modalities to address the multifactorial aspects of this disease process. Radiofrequency ablation (RFA) ... ...

Abstract	Background: The treatment of spine metastases continues to pose a significant clinical challenge, requiring the integration of multiple therapeutic modalities to address the multifactorial aspects of this disease process. Radiofrequency ablation (RFA) and vertebral cement augmentation (VCA) are 2 less invasive modalities compared to open surgery that have emerged as promising strategies, offering the potential for both pain relief and preservation of vertebral stability. The utility of these approaches, however, remains uncertain and subject to ongoing investigation.This systematic review and meta-analysis evaluates the available evidence and synthesize the results of studies that have investigated the combination of RFA and VCA for the treatment of spinal metastases, with the goal of providing a comprehensive and up-to-date assessment of the efficacy and safety of this therapeutic approach. Methods: A literature search was conducted using the electronic databases PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus from their inception to May 4th, 2022 in accordance with PRISMA guidelines. Studies were included if they met the following criteria: 1) spine metastases treated with RFA in combination with VCA, 2) available data on at least one outcome (i.e., pain palliation, complications, local tumor control), 3) prospective or retrospective studies with at least 10 patients, and 4) English language. Meta-analyses were conducted in R (R Foundation for Statistical Computing; Vienna, Austria), using the Results: In the 25 included studies, a total of 947 patients (females=53.9%) underwent RFA + VCA for spinal metastatic tumors. Out of 1,163 metastatic lesions, the majority were located in the lumbar region (585/1,163 [50.3%]) followed by thoracic (519/1,163 [44.6%]), sacrum (39/1,163 [3.4%]), and cervical (2/1,163 [0.2%]). 48/72 [66.7%] metastatic lesions expanded into the posterior elements. Preoperative pathologic vertebral fractures were identified in 115/176 [65.3%] patients. Between pre-procedure pain scores and postprocedure pain scores, average follow-up (FU) was 4.41±2.87 months. Pain scores improved significantly at a short-term FU (1-6 months), with a pooled mean difference (MD) from baseline of 4.82 (95% CI, 4.48-5.16). The overall local tumor progression (LTP) rate at short-term FU (1-6 months) was 5% (95% CI, 1%-8%), at mid-term FU (6-12 months) was 22% (95% CI, 0%-48%), and at long-term FU (>12 months) was 5% (95% CI, 0%-11%). The pooled incidence of total complications was 1% (95% CI, 0%-1%), the most frequent of which were transient radicular pain and asymptomatic cement extravasation. Conclusions: The findings of this meta-analysis reveal that the implementation of RFA in conjunction with VCA for the treatment of spinal metastatic tumors resulted in a significant short-term reduction of pain, with minimal total complications. The LTP rate was additionally low. The clinical efficacy and safety of this technique are established, although further exploration of the long-term outcomes of RFA+VCA is warranted.
Language	English
Publishing date	2024-02-23
Publishing country	United States
Document type	Journal Article ; Review
ISSN	2666-5484
ISSN (online)	2666-5484
DOI	10.1016/j.xnsj.2024.100317
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?

Vannabouathong, Christopher / Zhu, Meng / Chang, Yaping / Bhandari, Mohit

Clinical medicine insights. Arthritis and musculoskeletal disorders

2021 Volume 14, Page(s) 11795441211002492

Abstract: Introduction: Chronic knee pain is a common musculoskeletal condition, which usually leads to decreased quality of life and a substantial financial burden. Various non-surgical treatments have been developed to relieve pain, restore function and delay ... ...

Abstract	Introduction: Chronic knee pain is a common musculoskeletal condition, which usually leads to decreased quality of life and a substantial financial burden. Various non-surgical treatments have been developed to relieve pain, restore function and delay surgical intervention. Research on the benefits of medical cannabis (MC) is emerging supporting its use for chronic pain conditions. The purpose of this study was to evaluate the cost-effectiveness of MC compared to current non-surgical therapies for chronic knee pain conditions. Methods: We conducted a cost-utility analysis from a Canadian, single payer perspective and compared various MC therapies (oils, soft gels and dried flowers at different daily doses) to bracing, glucosamine, pharmaceutical-grade chondroitin oral non-steroidal anti-inflammatory drugs (NSAIDs), and opioids. We estimated the quality-adjusted life years (QALYs) gained with each treatment over 1 year and calculated incremental cost-utility ratios (ICURs) using both the mean and median estimates for costs and utilities gained across the range of reported values. The final ICURs were compared to willingness-to-pay (WTP) thresholds of $66 714, $133 428 and $200 141 Canadian dollars (CAD) per QALY gained. Results: Regardless of the estimates used (mean or median), both MC oils and soft gels at both the minimal and maximal recommended daily doses were cost-effective compared to all current knee pain therapies at the lowest WTP threshold. Dried flowers were only cost-effective up to a certain dosage (0.75 and 1 g/day based on mean and median estimates, respectively), but all dosages were cost-effective when the WTP was increased to $133 428/QALY gained. Conclusion: Our study showed that MC may be a cost-effective strategy in the management of chronic knee pain; however, the evidence on the medical use of cannabis is limited and predominantly low-quality. Additional trials on MC are definitely needed, specifically in patients with chronic knee pain.
Language	English
Publishing date	2021-03-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	2590933-2
ISSN	1179-5441
ISSN	1179-5441
DOI	10.1177/11795441211002492
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Management of pain due to cervical multilevel disk bulges and spinal stenosis with a focused vibro-percussion wave treatment: A case report.

Abu Omar, Arwa Jameel / Al Baradie, Mohammad Sami / Al Dera, Hussain / Vannabouathong, Christopher / Bartel, Lee

Clinical case reports

2022 Volume 10, Issue 4, Page(s) e05344

Abstract: A patient presenting with low back pain received 18 treatments of FDA-approved low-frequency vibro-percussion wave stimulation known as Khan Kinetic Treatment (KKT). Following KKT, he demonstrated improvement in pain, function, quality of life, sleep, ... ...

Abstract	A patient presenting with low back pain received 18 treatments of FDA-approved low-frequency vibro-percussion wave stimulation known as Khan Kinetic Treatment (KKT). Following KKT, he demonstrated improvement in pain, function, quality of life, sleep, and trunk range of motion with no adverse events.
Language	English
Publishing date	2022-04-04
Publishing country	England
Document type	Case Reports
ZDB-ID	2740234-4
ISSN	2050-0904
ISSN	2050-0904
DOI	10.1002/ccr3.5344
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Large, Multi-Center, Prospective Registry of Rezūm Water Vapor Therapy for Benign Prostatic Hyperplasia.

Elterman, Dean / Bhojani, Naeem / Vannabouathong, Christopher / Chughtai, Bilal / Zorn, Kevin C

Urology

2022 Volume 165, Page(s) 261–267

Abstract: Objective: To illustrate the role of Rezūm convective water vapor ablation for treatment of lower urinary tract symptoms secondary to Benign prostatic hyperplasia.: Methods: A prospective registry was established for Rezūm therapy in Canada at two ... ...

Abstract	Objective: To illustrate the role of Rezūm convective water vapor ablation for treatment of lower urinary tract symptoms secondary to Benign prostatic hyperplasia. Methods: A prospective registry was established for Rezūm therapy in Canada at two high-volume centers. All patients had baseline medical and Benign prostatic hyperplasia history documented, along with uroflowmetry and validated questionnaires up to 12 months post-surgery. Results: 229 patients (mean age 67.3 years), including 83 with prostate volumes ≥80 mL, were treated from April 2019 to December 2020. The mean prostate volume was 71.5 mL (range 20-160 mL) and 55% had a median lobe. The mean number of injections was 11 (range: 4-28) and mean procedural length was 4.8 minutes (range: 1.5-14). The mean duration of postprocedure catheterization was 9.8 days. International Prostate Symptom Scores improved from baseline by 29%, 53%, and 59% at 1, 3, and 12 months, respectively. International Prostate Symptom Scores quality of life improved from baseline by 30%, 50%, and 67% at 1, 3, and 12 months, respectively. Qmax improved by 60% at 3 months and 74% at 12 months. Post-void residual volume improved by 51% and 61% at 3 and 12 months, respectively. No statistically significant changes were seen in International Index of Erectile Function-15 or Male Sexual Health Questionnaire for Ejaculatory Dysfunction scores. No Clavien-Dindo events ≥Grade III occurred. Conclusion: Rezūm therapy is a safe, effective, and quick outpatient procedure for prostate glands over a wide range of volumes. Clinically significant improvements are seen in all validated questionnaires. Objective maximum flow measures improved, while erectile and ejaculatory function remains preserved.
MeSH term(s)	Aged ; Humans ; Lower Urinary Tract Symptoms/surgery ; Male ; Prostatic Hyperplasia/complications ; Prostatic Hyperplasia/diagnosis ; Prostatic Hyperplasia/surgery ; Quality of Life ; Registries ; Steam ; Treatment Outcome
Chemical Substances	Steam
Language	English
Publishing date	2022-02-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	192062-5
ISSN	1527-9995 ; 0090-4295
ISSN (online)	1527-9995
ISSN	0090-4295
DOI	10.1016/j.urology.2022.02.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1142: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 275: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Rezūm water vapor therapy for catheter-dependent urinary retention: a real-world Canadian experience.

Elterman, Dean S / Bhojani, Naeem / Vannabouathong, Christopher / Chughtai, Bilal / Zorn, Kevin C

The Canadian journal of urology

2022 Volume 29, Issue 2, Page(s) 11075–11079

Abstract: Introduction: This analysis reported outcomes of treating catheter-dependent urinary retention with Rezūm water vapor therapy.: Materials and methods: A prospective registry was established at two high-volume Canadian centers. Patients had baseline ... ...

Abstract	Introduction: This analysis reported outcomes of treating catheter-dependent urinary retention with Rezūm water vapor therapy. Materials and methods: A prospective registry was established at two high-volume Canadian centers. Patients had baseline medical and benign prostatic hyperplasia (BPH) history documented. The subgroup of patients with refractory, catheter-dependent urinary retention was analyzed. The primary outcome was the proportion of patients who were spontaneously voiding and catheter-free at 6 months. Results: Sixteen patients (age: 68.7 years) with catheter-dependent urinary retention were treated with Rezūm. Average prostate volume was 84.4 mL and 75% had median lobe. All patients had at least one recent failed trial without catheter (TWOC) and 87.5% were on BPH oral therapy. Mean number of vapor injections was 14.5. Visibility and bleeding during procedure were assessed using a 5-point scale, and were rated as 1.4 and 1.3, respectively. Anesthesia was either intravenous propofol sedation (n = 13) or self-administered methoxyflurane inhaler (n = 3). Mean catheter duration until first planned TWOC was 28.4 days. Three patients needed catheter replacement due to initial failed TWOC. One patient was lost to follow up, one patient did not return at 1 month, and one patient did not return at 3 months. At 1 month, 13/14 patients were spontaneously voiding and catheter-free. At 3 months, 14/14 patients were spontaneously voiding, and at 6 months, 15/15 patients were spontaneously voiding and catheter-free (1 patient was lost to follow up). Conclusions: Rezūm water vapor therapy can successfully treat catheter-dependent urinary retention after initial failed TWOC in an outpatient setting.
MeSH term(s)	Aged ; Canada ; Catheters ; Female ; Gases ; Humans ; Male ; Prostatic Hyperplasia/complications ; Prostatic Hyperplasia/surgery ; Steam ; Treatment Outcome ; Urinary Retention/etiology ; Urinary Retention/therapy
Chemical Substances	Gases ; Steam
Language	English
Publishing date	2022-04-16
Publishing country	Canada
Document type	Journal Article
ZDB-ID	2064475-9
ISSN	1195-9479
ISSN	1195-9479
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5607: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Rezūm therapy for ≥80-mL benign prostatic enlargement: a large, multicentre cohort study.

Elterman, Dean / Bhojani, Naeem / Vannabouathong, Christopher / Chughtai, Bilal / Zorn, Kevin C

BJU international

2022 Volume 130, Issue 4, Page(s) 522–527

Abstract: Objective: To evaluate the efficacy and safety of Rezūm therapy in benign prostatic hyperplasia (BPH) patients with prostates ≥80 mL.: Methods: A prospective registry was established at two high-volume Canadian centres. Patients had baseline medical ... ...

Abstract	Objective: To evaluate the efficacy and safety of Rezūm therapy in benign prostatic hyperplasia (BPH) patients with prostates ≥80 mL. Methods: A prospective registry was established at two high-volume Canadian centres. Patients had baseline medical history documented, and uroflowmetry and questionnaire results were recorded over 12 months. Results: Eighty-three patients (median [interquartile range {IQR}] age 69.2 [63.2, 74.8] years) with a prostate size ≥80 mL were included. The median (IQR) prostate volume was 100.0 (88.5, 115.0) mL and 65% had a median lobe. Twenty-one patients had prior urinary retention. The median (IQR) number of injections was 13 (11, 15) and catheterization duration was 9 (7, 14) days. International Prostate Symptom Scores (IPSSs) improved by 24%, 57% and 59% at 1, 3 and 12 months, respectively (P < 0.001). IPSS Quality of Life (QoL) scores improved by 27%, 56% and 70% at these same timepoints (P < 0.001). Maximum urinary flow rate improved by 55% at 3 months (P = 0.002) and 59% at 12 months, and post-void residual urine volume improved by 58% at 3 months (P = 0.006). BPH Impact Index scores improved by 57% at 3 months and 71% at 12 months. International Index of Erectile Function-15 scores improved by 15% at 6 months, and Male Sexual Health Questionnaire for Ejaculatory Dysfunction scores improved by 22.4% at 1 month. Three patients (3.6%) noted reduced/anejaculation. No events of Clavien-Dindo grade III or higher occurred. Conclusion: This study demonstrates, for the first time, the safety and efficacy of Rezūm therapy in large glands >80 mL. IPSS improved by 59% and IPSS QoL score improved by 70% at 12 months. Objective maximum urinary flow measures improved at 12 months by 59%, while erectile and ejaculatory function remained preserved.
MeSH term(s)	Aged ; Canada ; Cohort Studies ; Humans ; Lower Urinary Tract Symptoms/therapy ; Male ; Prostatic Hyperplasia/therapy ; Quality of Life ; Treatment Outcome
Language	English
Publishing date	2022-05-07
Publishing country	England
Document type	Journal Article ; Multicenter Study
ZDB-ID	1462191-5
ISSN	1464-410X ; 1464-4096 ; 1358-8672
ISSN (online)	1464-410X
ISSN	1464-4096 ; 1358-8672
DOI	10.1111/bju.15753
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.107: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 13: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comparing medical cannabis use in 5 US states: a retrospective database study.

Mahabir, V Kishan / Smith, Christopher S / Vannabouathong, Christopher / Merchant, Jamil J / Garibaldi, Alisha L

Journal of cannabis research

2021 Volume 3, Issue 1, Page(s) 15

Abstract: Background: US states have been adopting their own medical cannabis laws since 1996. There is substantial variability in the medical cannabis programs between states, and these differences have not been thoroughly investigated in the literature. The ... ...

Abstract	Background: US states have been adopting their own medical cannabis laws since 1996. There is substantial variability in the medical cannabis programs between states, and these differences have not been thoroughly investigated in the literature. The objective of the study was to compare medical cannabis patient characteristics across five states to identify differences potentially caused by differing policies surrounding condition eligibility. Methods: We conducted secondary analyses following a retrospective study of a registry database with data from 33 medical cannabis evaluation clinics in the US, owned and operated by CB2 Insights. This study narrowed the dataset to include patients from five states with the largest samples: Massachusetts (n = 27,892), Colorado (n = 16,434), Maine (n = 4591), Connecticut (n = 2643), and Maryland (n = 2403) to conduct an in-depth study of the characteristics of patients accessing medical cannabis in these states, including analysis of variance to compare average ages and number of conditions and chi-squared tests to compare proportions of patient characteristics between states. Results: Average ages varied between the states, with the youngest average in Connecticut (42.2) and the oldest in Massachusetts (47.0). Males represented approximately 60% of the patients with data on gender in each state. The majority of patients in each state had cannabis experience prior to seeking medical certification. Primary medical conditions varied for each state, with chronic pain, anxiety, and back and neck problems topping the list in varying orders for Massachusetts, Maine, and Maryland. Colorado had 78.7% of patients report chronic pain as their primary condition, and 70.4% of patients in Connecticut reported post-traumatic stress disorder as their primary medical condition. Conclusion: This study demonstrated the significant impact that policy has on patients' access to medical cannabis in Massachusetts, Colorado, Maine, Connecticut, and Maryland utilizing real-world data. It highlights how qualifications differ between the five states and brings into question the routes through which patients in states with stricter regulations surrounding eligible conditions choose to seek treatment with cannabis. These patients may turn to alternative treatments, or to the illicit or recreational cannabis markets, where permitted.
Language	English
Publishing date	2021-05-27
Publishing country	England
Document type	Journal Article
ISSN	2522-5782
ISSN (online)	2522-5782
DOI	10.1186/s42238-021-00075-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Closed Limb Fractures With Compromised Vascularization: A Narrative Review.

Vannabouathong, Christopher / Schemitsch, Emil / Petrisor, Bradley / Bhandari, Mohit

Clinical medicine insights. Arthritis and musculoskeletal disorders

2019 Volume 12, Page(s) 1179544119836742

Abstract: Vascular compromised fractures typically result in a high rate of healing complications, such as avascular necrosis, nonunion, delayed union, and arthritis, which severely affect a patient's function and quality of life. The purpose of this review was to ...

Abstract	Vascular compromised fractures typically result in a high rate of healing complications, such as avascular necrosis, nonunion, delayed union, and arthritis, which severely affect a patient's function and quality of life. The purpose of this review was to identify and describe the epidemiology and available treatment options for the most well-known vascular compromised closed fractures. The injuries discussed in detail in this review were scaphoid, lunate, femoral neck, and talar fractures. Current evidence suggests that optimal treatment for vascular compromised fractures is dependent on the degree of fracture displacement and comminution, and the patient's post-injury functional demands, age, and bone quality. Conservative efforts generally include casting or splinting with a period of immobilization. Surgery is indicated for substantially displaced fractures, patients who require higher functional demands and an earlier return to activity, or if complications occur following nonoperative treatment; however, operative intervention is typically performed for femoral neck fractures regardless of the amount of displacement. Various surgical techniques exist, though internal fixation with screws is a common procedure among these injuries and can be used in combination with other implants, such as plating or Kirschner wires (k-wires), when needed. Severe fracture comminution, poor bone quality, or arthritis can contraindicate the use of screws and more invasive intervention will be required. Bone grafting is done in some cases to enhance vascularity. Salvage procedures exist for patients who develop severe complications, but these will permanently alter the anatomy of the injured area and should be considered a last resort.
Language	English
Publishing date	2019-03-18
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2590933-2
ISSN	1179-5441
ISSN	1179-5441
DOI	10.1177/1179544119836742
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?

Johal, Herman / Vannabouathong, Christopher / Chang, Yaping / Zhu, Meng / Bhandari, Mohit

Therapeutic advances in musculoskeletal disease

2020 Volume 12, Page(s) 1759720X20937968

Abstract: The treatment of chronic, non-cancer musculoskeletal pain has become a topic growing interest as it is believed to be one of the reasons for the current opioid epidemic. The medicinal use of cannabis has a long history as a number of active compounds in ... ...

Abstract	The treatment of chronic, non-cancer musculoskeletal pain has become a topic growing interest as it is believed to be one of the reasons for the current opioid epidemic. The medicinal use of cannabis has a long history as a number of active compounds in cannabis have been shown to interact with the body's endocannabinoid system to reduce pain. This position paper provides a history on the evolution of cannabis, the science behind its therapeutic effects, and review of the evidence and current guideline recommendations on its use as a treatment for patients with chronic, non-cancer musculoskeletal pain. Results from systematic reviews have demonstrated a statistically significant reduction in chronic pain conditions with cannabinoids, compared with placebo, although the effects might be considered small and did not reach the minimally important difference. More adverse events were reported in the cannabinoid group than in the placebo group with longer than 2 weeks of treatment. There is a lack of evidence on dependence. With changes to policies, patients' perception has changed to be more positive toward the use of medical cannabis. Current recommendations from North America, Latin America, Europe, Australia and Iran support the use of medical cannabis for chronic, non-cancer pain. Based on the current evidence, it is our position that cannabinoids may be considered as an adjunctive therapy after recommended first- and second-line therapies have failed to provide sufficient efficacy or tolerability. Patients should consider the balance between the desirable and undesirable effects of taking cannabis for chronic pain, and comprehensively consider their own values and preferences, as well as cost-effectiveness factors, based on the information provided by their physician.
Language	English
Publishing date	2020-07-02
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2516075-8
ISSN	1759-7218 ; 1759-720X
ISSN (online)	1759-7218
ISSN	1759-720X
DOI	10.1177/1759720X20937968
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito